ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a fixed-dose combination oral tablet containing chloroquine phosphate and primaquine phosphate, two antimalarial agents with synergistic activity. This combination is indicated for the treatment and suppression of malaria, particularly for radical cure of P. vivax and P. ovale infections where primaquine eliminates hypnozoites. The fixed combination optimizes compliance by simplifying dosing regimens for patients requiring dual antimalarial therapy.
LOE Approaching
With LOE approaching and limited commercial infrastructure indicated by zero linked jobs, this mature product represents a maintenance-mode assignment rather than a growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product currently shows zero linked job openings, reflecting its LOE-approaching status and minimal hiring activity. Working on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE would be a maintenance role focused on lifecycle management, compliance, and managed decline rather than career acceleration through innovation or growth.
Brand ManagerField Sales
Worked on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.